AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26847031 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group attendance (8 weekly sessions of 2 hours each)
Number of subjects: 33
Study 24184274 — intervention group
Group type: EXPERIMENTAL
Intervention: BR+Ex (combined aerobic and resistive exercises)
Number of subjects: 0
Study 24184274 — intervention group
Group type: EXPERIMENTAL
Intervention: BR+Nut (nutritional leucine and valine diet)
Number of subjects: 0
Study 24184274 — intervention group
Group type: COMPARATOR
Intervention: BR (bed rest only)
Number of subjects: 0
Study 21397126 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone calls to patients after discharge
Number of subjects: 50
Study 19274316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg (1 ml) of morphine diluted in 9 ml of saline
Number of subjects: 39
Study 19274316 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg (10 ml) of 0.25% bupivacaine without epinephrine
Number of subjects: 39
Study 17370787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 1.5 mg/kg
Number of subjects: 70
Study 17370787 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 0.1 mg/kg
Number of subjects: 70
Study 12655910 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support (initiated within 48 to 72 hours of randomization) from a trained mother who previously experienced PPD.
Number of subjects: 42
Study 12655910 — intervention group
Group type: COMPARATOR
Intervention: Standard community postpartum care (control group).
Number of subjects: 42
Study 10734596 — intervention group
Group type: EXPERIMENTAL
Intervention: Early water contact with or without shower foam from the second postoperative day
Number of subjects: 817
Study 10734596 — intervention group
Group type: COMPARATOR
Intervention: Wounds kept dry until stitches were removed
Number of subjects: 817
Study 8882904 — intervention group
Group type: COMPARATOR
Intervention: V0.1-rest in normal subjects (Nor: 0.25 +/- 0.10 l/s), CPE (0.27 +/- 0.06 l/s), IP (0.26 +/- 0.06 l/s)
Number of subjects: 15
Study 8882904 — intervention group
Group type: COMPARATOR
Intervention: P0.1-rest in normal subjects (Nor: 1.98 +/- 0.61 hPa), CPE (3.00 +/- 0.80 hPa), IP (3.60 +/- 0.68 hPa)
Number of subjects: 15
Study 8882904 — intervention group
Group type: COMPARATOR
Intervention: V0.1-max in normal subjects (Nor: 3.66 +/- 1.16 l/s), CPE (0.82 +/- 0.25 l/s), IP (1.02 +/- 0.21 l/s)
Number of subjects: 15
Study 8882904 — intervention group
Group type: COMPARATOR
Intervention: P0.1-max in normal subjects (Nor: 33.2 +/- 10.2 hPa), CPE (9.8 +/- 3.7 hPa), IP (19.5 +/- 3.4 hPa)
Number of subjects: 15
Study 1607430 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam core build-up
Number of subjects: 87
Study 1607430 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite core build-up
Number of subjects: 87
Study 3884032 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional superficial X-ray therapy (300 rad, 3 Gy)
Number of subjects: 25
Study 3884032 — intervention group
Group type: COMPARATOR
Intervention: Grenz ray therapy (900 rad, 9 Gy)
Number of subjects: 25
Study 30203866 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 20
Study 30203866 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise
Number of subjects: 20
Study 30203866 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 20
Study 26778191 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis based on T1-weighted MRI
Number of subjects: 53
Study 26778191 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis based on T2-weighted MRI
Number of subjects: 53
Study 26778191 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis based on diffusion-weighted MRI
Number of subjects: 53
Study 26778191 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised learning models based on T1 sequence
Number of subjects: 53
Study 26778191 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised learning models based on T2 W
Number of subjects: 53
Study 26778191 — intervention group
Group type: COMPARATOR
Intervention: Comparison of two classifiers
Number of subjects: 53
Study 24861886 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphinol® (maqui berry extract)
Number of subjects: 10
Study 22017365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite extract for 2 years
Number of subjects: 251
Study 22017365 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 251
Study 22017365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 251
Study 22017365 — intervention group
Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) and Placebo
Number of subjects: 251
Study 20636999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream B (cosmetic emulsion with active ingredients: soy and jasmine)
Number of subjects: 24
Study 20636999 — intervention group
Group type: COMPARATOR
Intervention: Cream A (vehicle without active ingredients)
Number of subjects: 24
Study 18569241 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer programs with teacher-led presentation
Number of subjects: 871
Study 18569241 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of computer programs and teacher-led presentation
Number of subjects: 871
Study 18569241 — intervention group
Group type: COMPARATOR
Intervention: Teacher-led presentation
Number of subjects: 871
Study 16055571 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 one-hour sessions per week)
Number of subjects: 92
Study 16055571 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly relaxation and focus group discussions)
Number of subjects: 92
Study 16055571 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 92
Study 12448352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin (0.4 mumol/L)
Number of subjects: 12
Study 12448352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin (2 mumol/L)
Number of subjects: 12
Study 12448352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin (10 mumol/L)
Number of subjects: 12
Study 12448352 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 10598433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine/bupivacaine (25 ml of 0.25% bupivacaine and 2 mg of morphine)
Number of subjects: 40
Study 10598433 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diclofenac i.m. (75 mg) and intraarticular morphine/bupivacaine
Number of subjects: 40
Study 10598433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac i.m. (75 mg)
Number of subjects: 40
Study 10598433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8564134 — intervention group
Group type: EXPERIMENTAL
Intervention: auto-CPAP (Morphée Plus)
Number of subjects: 16
Study 8564134 — intervention group
Group type: COMPARATOR
Intervention: constant-CPAP (Morphée Plus)
Number of subjects: 16
Study 1752623 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice a day long acting sustained release isosorbide dinitrate (SRISDN)
Number of subjects: 18
Study 1752623 — intervention group
Group type: COMPARATOR
Intervention: Four times daily short acting isosorbide dinitrate
Number of subjects: 18
Study 7091638 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg domperidone
Number of subjects: 2
Study 7091638 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antiemetic medication (control group)
Number of subjects: 2
Study 30892124 — intervention group
Group type: EXPERIMENTAL
Intervention: BhCG days 1-4 follow-up protocol
Number of subjects: 0
Study 30892124 — intervention group
Group type: EXPERIMENTAL
Intervention: BhCG days 1-7 follow-up protocol
Number of subjects: 0
Study 30892124 — intervention group
Group type: COMPARATOR
Intervention: BhCG day 4-7 follow-up protocol
Number of subjects: 0
Study 27875287 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose AAs (2.4 g/[kg·d]) and SOY (n = 24)
Number of subjects: 142
Study 27875287 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose AAs (2.4 g/[kg·d]) and MIX (n = 25)
Number of subjects: 142
Study 27875287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AAs (3.6 g/[kg·d]) and SOY (n = 24)
Number of subjects: 142
Study 27875287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AAs (3.6 g/[kg·d]) and MIX (n = 23)
Number of subjects: 142
Study 26995372 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 120
Study 26995372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25256185 — intervention group
Group type: EXPERIMENTAL
Intervention: Retirement Village Physical Activity and Nutrition for Seniors (RVPANS) programme, a home-based physical activity and nutrition programme with educational resources and facilitators for 6 months.
Number of subjects: 400
Study 25256185 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care or no intervention).
Number of subjects: 400
Study 22743591 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 20
Study 22743591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20586755 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-cue exposure
Number of subjects: 20
Study 20586755 — intervention group
Group type: COMPARATOR
Intervention: Control-cue exposure (sniffed water)
Number of subjects: 20
Study 17494885 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptitration of benazepril (median 20 mg/d; range 10 to 40)
Number of subjects: 360
Study 17494885 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptitration of losartan (median 100 mg/d; range 50 to 200)
Number of subjects: 360
Study 17494885 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage of benazepril (10 mg/d)
Number of subjects: 360
Study 17494885 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage of losartan (50 mg/d)
Number of subjects: 360
Study 16334026 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Pap smear
Number of subjects: 12107
Study 16334026 — intervention group
Group type: EXPERIMENTAL
Intervention: Autocyte PREP (LBC)
Number of subjects: 12107
Study 16334026 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA‐Citoliq (LBC)
Number of subjects: 12107
Study 16334026 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture II (HCII)
Number of subjects: 12107
Study 11804989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning with a 120-second coronary occlusion
Number of subjects: 56
Study 11804989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (an agonist of K(ATP) channels)
Number of subjects: 56
Study 11804989 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (an antagonist of K(ATP) channels)
Number of subjects: 56
Study 11804989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic period lengthened to 180 seconds
Number of subjects: 56
Study 9935014 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (1 to 3 times the upper normal limit)
Number of subjects: 3535
Study 9935014 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (3 to 5 times normal)
Number of subjects: 3535
Study 9935014 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (5 to 10 times normal)
Number of subjects: 3535
Study 9935014 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (>10 times normal)
Number of subjects: 3535
Study 9935014 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (any elevation)
Number of subjects: 3535
Study 9935014 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated total CK levels (above three times normal)
Number of subjects: 3535
Study 8678248 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh blade
Number of subjects: 20
Study 8678248 — intervention group
Group type: COMPARATOR
Intervention: McCoy blade
Number of subjects: 20
Study 2348469 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm-modulated rate (schedule B)
Number of subjects: 23
Study 2348469 — intervention group
Group type: COMPARATOR
Intervention: Constant rate (schedule A)
Number of subjects: 23
Study 103358 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg x 3-4 per day, starting 1-2 days before menstruation
Number of subjects: 95
Study 103358 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg x 3-4 per day, starting on the first day of bleeding
Number of subjects: 95
Study 103358 — intervention group
Group type: COMPARATOR
Intervention: Naproxen-sodium (double-blind crossover)
Number of subjects: 95
Study 31959202 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-based supplement (13.2g carbohydrates; 3.2g BCAA; 1.6g L-alanine per dose)
Number of subjects: 32
Study 31959202 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-based supplement
Number of subjects: 32
Study 31016887 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle activating measures (neuromuscular electrical stimulation or whole-body vibration) in addition to early protocol-based physiotherapy
Number of subjects: 50
Study 31016887 — intervention group
Group type: COMPARATOR
Intervention: Early protocol-based physiotherapy alone (control)
Number of subjects: 50
Study 28611274 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 9
Study 28611274 — intervention group
Group type: COMPARATOR
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 9
Study 28611274 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 9
Study 24989842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (14,000 units once weekly for 6 weeks)
Number of subjects: 39
Study 24989842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23414658 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-hour communication skills course
Number of subjects: 62
Study 22164761 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Lentinex for 6 weeks
Number of subjects: 42
Study 22164761 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 42
Study 22164761 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Lentinex
Number of subjects: 42
Study 22164761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22164761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinex
Number of subjects: 42
Study 19673020 — intervention group
Group type: EXPERIMENTAL
Intervention: Split dose midazolam in combination with meperidine (Group A)
Number of subjects: 80
Study 19673020 — intervention group
Group type: COMPARATOR
Intervention: Single dose midazolam in combination with meperidine (Group B)
Number of subjects: 80
Study 16771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Number of subjects: 50
Study 16771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Number of subjects: 50
Study 16771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Number of subjects: 50
Study 16771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Number of subjects: 50
Study 16771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose pegylated interferon alpha-2b + ribavirin for genotype 1
Number of subjects: 50
Study 16771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pegylated interferon alpha-2b + ribavirin for genotype 1
Number of subjects: 50
Study 16771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses exceeding the 1-2-5 threshold for genotype 1
Number of subjects: 50
Study 15596921 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative whole brain radiotherapy (WBRT) (n = 49 patients)
Number of subjects: 95
Study 15596921 — intervention group
Group type: COMPARATOR
Intervention: No further brain treatment (n = 46 patients)
Number of subjects: 95
Study 15596921 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative whole brain radiotherapy (WBRT)
Number of subjects: 95
Study 12161766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 141
Study 12161766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 9848882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol and 2.5 mg medroxyprogesterone (n=7)
Number of subjects: 23
Study 9848882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol alone (n=8)
Number of subjects: 23
Study 9848882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 23
Study 8119527 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal duodenal distention (10, 20, 30 mL of air) during fasting
Number of subjects: 12
Study 8119527 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal duodenal distention (10, 20, 30 mL of air) during fasting
Number of subjects: 12
Study 8119527 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal duodenal distention (10, 20, 30 mL of air) postprandially
Number of subjects: 12
Study 8119527 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal duodenal distention (10, 20, 30 mL of air) postprandially
Number of subjects: 12
Study 8119527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both proximal and distal duodenal distention during fasting and postprandially
Number of subjects: 12
Study 8119527 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal duodenal distention during fasting
Number of subjects: 12
Study 2680866 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon therapy (90 million units per m2 total dose over 12 weeks)
Number of subjects: 114
Study 336652 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pentobarbital
Number of subjects: 0
Study 336652 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg methyprylon
Number of subjects: 0
Study 336652 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg glutethimide
Number of subjects: 0
Study 336652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30913347 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative trauma-related cognitions
Number of subjects: 137
Study 28661970 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection + postresuscitation care bundle
Number of subjects: 978
Study 28661970 — intervention group
Group type: COMPARATOR
Intervention: Postresuscitation care bundle
Number of subjects: 978
Study 25534960 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrate beverage
Number of subjects: 11
Study 25534960 — intervention group
Group type: COMPARATOR
Intervention: Low nitrate beverage
Number of subjects: 11
Study 22782737 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention for smoking cessation
Number of subjects: 60
Study 22782737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 21830957 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg daily)
Number of subjects: 14264
Study 21830957 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 14264
Study 19804594 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nicotinamide (0.2% or 5%)
Number of subjects: 4
Study 19804594 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 4
Study 16735702 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy containing one course with standard dose and one course with high-dose cytarabine
Number of subjects: 1770
Study 16735702 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy containing two courses with high-dose cytarabine
Number of subjects: 1770
Study 16735702 — intervention group
Group type: EXPERIMENTAL
Intervention: Postremission therapy by prolonged maintenance
Number of subjects: 1770
Study 16735702 — intervention group
Group type: COMPARATOR
Intervention: Postremission therapy by busulfan/cyclophosphamide chemotherapy with autologous stem-cell transplantation
Number of subjects: 1770
Study 16735702 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy and postremission therapy
Number of subjects: 1770
Study 15556150 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocysteine lysine salt monohydrate (SCMC-Lys) for 6 months
Number of subjects: 55
Study 11292473 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient group (self-administered misoprostol)
Number of subjects: 87
Study 11292473 — intervention group
Group type: COMPARATOR
Intervention: Inpatient group (administered misoprostol in hospital)
Number of subjects: 87
Study 9123740 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of leuprolide acetate and flutamide (androgen deprivation)
Number of subjects: 137
Study 9123740 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy alone (control)
Number of subjects: 137
Study 9123740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir PSA ≤ 0.1 ng/mL
Number of subjects: 137
Study 9123740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir PSA > 0.1 ng/mL
Number of subjects: 137
Study 30154502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 5887
Study 30154502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy and Oophorectomy
Number of subjects: 5887
Study 30154502 — intervention group
Group type: COMPARATOR
Intervention: Control (No Surgery)
Number of subjects: 5887
Study 27539689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14171
Study 27539689 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term DAPT (≥30 days)
Number of subjects: 14171
Study 27539689 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy
Number of subjects: 14171
Study 27539689 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT to monotherapy switch
Number of subjects: 14171
Study 27539689 — intervention group
Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy after PCI
Number of subjects: 14171
Study 27539689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke/systemic embolism rate
Number of subjects: 14171